Vivitrol naltrexone regulatory update

FDA's Psychopharmacologic Drugs Advisory Committee voted 12-1 to recommend approval of an sNDA from Alkermes to extend the label for Vivitrol naltrexone to prevent relapse to opioid use in opioid-depe...